Published online Feb 19, 2024. doi: 10.5498/wjp.v14.i2.194
Peer-review started: October 8, 2023
First decision: November 30, 2023
Revised: December 2, 2023
Accepted: January 2, 2024
Article in press: January 2, 2024
Published online: February 19, 2024
Processing time: 120 Days and 22.4 Hours
Women represent the majority of patients with psychiatric diagnoses and also the largest users of psychotropic drugs. There are inevitable differences in efficacy, side effects and long-term treatment response between men and women. Psychopharmacological research needs to develop adequately powered animal and human trials aimed to consider pharmacokinetics and pharmacodynamics of central nervous system drugs in both male and female subjects. Healthcare professionals have the responsibility to prescribe sex-specific psychopharmacotherapies with a priority to differentiate between men and women in order to minimize adverse drugs reactions, to maximize therapeutic effectiveness and to provide personalized management of care.
Core Tip: It has been largely demonstrated that women are the majority of patients with psychiatric diagnoses and also the largest users of psychotropic drugs. There are differences between men and women receiving psychotropic drugs, in terms of response, efficacy, side effects, long-term treatment outcome. There is still a lack of psychopharmacological research focusing on these differences in male and female patients. This editorial focuses on the important issue of deeply understanding the pharmacokinetics and pharmacodynamics of central nervous system drugs with a priority to differentiate between men and women in order to provide personalized management of care.